ANURADHA THIRUMALAI: Open Payments
NPI 1306217534 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,759 in 241 payments from 36 companies in 2025. Trend: 2023 $3,569 · 2024 $5,449 · 2025 $5,759
Food & beverage: $5,689Education: $70
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 37 | $665 |
| Biogen, Inc. | 22 | $584 |
| UCB, Inc. | 16 | $550 |
| ARGENX US, INC. | 11 | $401 |
| Genentech USA, Inc. | 12 | $395 |
| EMD Serono, Inc. | 11 | $334 |
| Celgene Corporation | 19 | $276 |
| Lilly USA, LLC | 9 | $239 |
| Otsuka America Pharmaceutical, Inc. | 12 | $234 |
| Novartis Pharmaceuticals Corporation | 21 | $217 |
Products named: QULIPTA, VYVGART HYTRULO, REXULTI, TYSABRI, ZEPOSIA, Nayzilam, Ocrevus Zunovo, Briviact.
Industry payments across NV — which companies pay providers there.
